Publications by authors named "Sofia SchueSSler"
Article Synopsis
- - Tafamidis is the first drug approved to treat transthyretin amyloid cardiomyopathy (ATTR-CM) in adults, aiming to lower the risk of cardiovascular death and related hospitalizations, but its real-world usage in Germany is not well understood
- - A study analyzed data from 1,565 adults who filled a tafamidis prescription between March 2020 and August 2022, finding that the average age of participants was 78.3 years, with a majority being male and treated mostly by cardiologists
- - Results showed high adherence and persistency rates for tafamidis, with 78% of patients continuing treatment after 12 months and significant numbers consistently filling prescriptions, indicating the drug is generally well-t
